title: The business case for patient safety.
abstract: Recent trends have focused attention on improving patient safety in the United States healthcare system. Lapses in patient safety create undue, often preventable, morbidity. These include adverse drug events, adverse surgical events and nosocomial infections. From an organizational perspective, these events are both inefficient and expensive. Many safe practices and quality enhancing improvements, such as computer provider order entry, proper infection surveillance, telemedicine intensive care, and registered nurse staffing are in fact cost-effective. However, in order to fully achieve higher quality, better adverse event reporting and a culture of safety must first be developed. Increased provider recognition, models of success, public awareness and consumer demand are propelling improvements. As we will outline in this review of the current literature, the business case for patient safety is a compelling one, offering substantial economic incentives for achieving the necessary goal of improved patient outcomes.
authors.affiliation: Harvard Combined Orthopaedic Residency Program, Partners Health System, Boston, MA 02114, USA. jherndon@partners.org
authors.forename: Raymond W
authors.initials: RW
authors.lastname: Hwang
authors.forename: James H
authors.initials: JH
authors.lastname: Herndon
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D003428:Cross Infection / Q000191:economics; D003466:Cultural Characteristics; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007431:Intraoperative Complications / Q000191:economics; D004364:Pharmaceutical Preparations / Q000191:economics; D011183:Postoperative Complications / Q000191:economics; D011785:Quality Assurance, Health Care / Q000191:economics*; D011787:Quality of Health Care / Q000191:economics*; D017751:Safety Management / Q000191:economics*
chemical_list: D004364:Pharmaceutical Preparations